Drug Trial Radar · NCT06321302
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
175
Planned (sponsor's estimate)
Start
May 15, 2024
Primary completion
Mar 5, 2027
Study completion Aug 20, 2027
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Mar 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study. The purpose of this study is to find out whether a medicine called BI 764524 helps people with diabetic retinopathy. The study also aims to find a suitable treatment plan for BI 764524. Participants are put into 5 groups by chance. Participants in groups 1, 2, and 3 get BI 764524. Over 1 year, they get a different number of injections of the same dose of BI 764524 injected into 1 eye. During some visits, participants may get a sham control, which is done like an eye injection but without a needle, so that participants will not know how many injections of BI 764524 they received. Participants in group 4 only get a sham control. Participants in group 5 (only in the USA) get aflibercept or sham injections during some visits. Aflibercept is a medicine already used to treat diabetic retinopathy. Participants are in the study for one and a half years. During this time, they visit the study site at least 16 times. During this time, doctors regularly do eye exams and visual tests to assess the severity of participants' eye condition. After 1 year of treatment, researchers look at the number of participants with eye improvements. To do so, they compare eye damage and certain severe eye problems between the groups of participants. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Diabetic Retinopathy
Interventions
BI 764524Drug
BI 764524
Sham comparator to BI 764524Drug
Sham comparator to BI 764524
Aflibercept (Eylea®) - US onlyDrug
Aflibercept (Eylea®) - US only
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of a ≥2-step improvement compared with baseline in Diabetic Retinopathy Severity Scale (DRSS) level in the study eye at Week 52 as assessed by Ultra-widefield colour fundus photography (UWF-CFP) images (within the 7-field grid)Time frame: At baseline and at Week 52
Locations
90 sites in 9 countries. Site status is shown where the registry gives one.
Associated Retina Consultants, Ltd.
Phoenix, Arizona · Active not recruiting
California Retina Consultants-Bakersfield-65523
Bakersfield, California · Active not recruiting
Retina-Vitreous Associates Medical Group
Beverly Hills, California · Active not recruiting
Retinal Diagnostic Center
Campbell, California · Completed
The Retina Partners
Encino, California · Active not recruiting
Lugene Eye Institute
Glendale, California · Active not recruiting
Retina Associates of Southern California
Huntington Beach, California · Active not recruiting
Byers Eye Institute
Palo Alto, California · Completed
California Eye Specialists Medical Group Inc
Pasadena, California · Active not recruiting
Retinal Consultants Medical Group
Sacramento, California · Active not recruiting
Retinal Consultants Medical Group
Sacramento, California · Active not recruiting
California Retina Consultants-Santa Maria-65510
Santa Maria, California · Active not recruiting
Bay Area Retina Associates - Walnut Creek
Walnut Creek, California · Active not recruiting
Colorado Retina Associates
Lakewood, Colorado · Active not recruiting
Retina Group of New England, PC
Waterford, Connecticut · Completed
Florida Retina Institute
Jacksonville, Florida · Recruiting
Florida Retina Consultants
Lakeland, Florida · Active not recruiting
East Florida Eye Institute
Stuart, Florida · Active not recruiting
Center for Retina and Macular Disease
Winter Haven, Florida · Active not recruiting
Retina Consultants Of Hawaii
‘Aiea, Hawaii · Active not recruiting
Maine Eye Center
Portland, Maine · Active not recruiting
Cumberland Valley Retina Consultants
Hagerstown, Maryland · Active not recruiting
Deep Blue Retina Clinical Research PLLC
Southaven, Mississippi · Active not recruiting
NJRetina
Teaneck, New Jersey · Active not recruiting
Long Island Vitreoretinal Consultants
Great Neck, New York · Completed
Retina Vitreous Surgeons of Central NY, PC
Liverpool, New York · Active not recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Active not recruiting
EyeHealth Northwest
Portland, Oregon · Completed
Charleston Neuroscience Institute - Ladson
Ladson, South Carolina · Completed
Tennessee Retina
Nashville, Tennessee · Active not recruiting
Austin Retina Associates
Austin, Texas · Active not recruiting
Retina Research Center, PLLC
Austin, Texas · Active not recruiting
Austin Clinical Research, LLC
Austin, Texas · Active not recruiting
Retina Consultants of Texas
Katy, Texas · Active not recruiting
Valley Retina Institute, PA
McAllen, Texas · Completed
Austin Retina Associates
Round Rock, Texas · Completed
Medical Center Ophthalmology Associates
San Antonio, Texas · Active not recruiting
Retina Consultants of Texas
San Antonio, Texas · Active not recruiting
Retina Consultants of Texas - Schertz
Schertz, Texas · Completed
Retina Associates of Utah
Salt Lake City, Utah · Recruiting
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.